menu
    • menu
    [{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TP-317","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Thetis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"TP-317","moa":"BLT1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust"}]

    Find Clinical Drug Pipeline Developments & Deals for TP-317

    Menu

    TP-317

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Thetis Pharmaceuticals

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            Thetis Pharmaceuticals

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-317

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Helmsley Charitable Trust

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Thetis Secures $8.975M to Advance TP-317 for Ulcerative Colitis Trial

                            Details : The funding is intended to support the clinical development of TP-317, an early-stage product, in patients with ulcerative colitis, focusing on identifying safe and effective dosing.

                            Product Name : TP-317

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : TP-317

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Helmsley Charitable Trust

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Thetis Pharmaceuticals

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            Thetis Pharmaceuticals

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-317

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Thetis Reports Positive Initial Phase 1a Results for TP-317 in Healthy Subjects

                            Details : P-317 is an oral BLT1 agonist, small molecule therapy based on Resolvin E1 (RvE1) for the treatment of inflammatory bowel disease (IBD) and cancer.

                            Product Name : TP-317

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 31, 2024

                            Lead Product(s) : TP-317

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth